ImmunityBio (NASDAQ:IBRX) Trading Up 6.2%

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) were up 6.2% during mid-day trading on Thursday . The company traded as high as $5.82 and last traded at $5.80. Approximately 1,988,923 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 3,987,718 shares. The stock had previously closed at $5.46.

Analyst Ratings Changes

Separately, Piper Sandler upped their price target on ImmunityBio from $4.00 to $5.00 and gave the company a “neutral” rating in a research report on Monday.

ImmunityBio Stock Down 1.6 %

The business has a 50-day moving average price of $4.57 and a 200-day moving average price of $3.61. The firm has a market capitalization of $3.62 billion, a PE ratio of -4.63 and a beta of 1.24.

Institutional Investors Weigh In On ImmunityBio

A number of large investors have recently made changes to their positions in IBRX. Point72 Hong Kong Ltd grew its position in ImmunityBio by 2,136.0% in the first quarter. Point72 Hong Kong Ltd now owns 6,149 shares of the company’s stock worth $34,000 after acquiring an additional 5,874 shares during the period. Tower Research Capital LLC TRC grew its position in ImmunityBio by 43.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,393 shares of the company’s stock worth $47,000 after acquiring an additional 2,844 shares during the period. Meridian Management Co. purchased a new position in ImmunityBio in the fourth quarter worth approximately $46,000. Private Advisor Group LLC purchased a new position in ImmunityBio in the fourth quarter worth approximately $53,000. Finally, Gotham Asset Management LLC purchased a new position in ImmunityBio in the fourth quarter worth approximately $54,000. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.